SEngine Precision Medicine

United States
Seattle, Washington, United States, 98109

Company profile

SEngine Precision Medicine company profile

SEngine Precision Medicine uses algorithms and 3D organoid technology to develop drugs with more efficacy. It empowers patients and oncologists with more informed treatment options. The company's technology simultaneously tests more than 200 cancer drugs against a patient's unique tumor organoid outside the body. The results decode the most effective and least toxic treatment options that DNA sequencing alone cannot reveal. Its proprietary platform leverages the aggregated, anonymized test results to develop new cancer-fighting drugs.

Business identity

Contact email
[email protected]
Phone number
(833) 736-4163
Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Revenue range
$0-$1M
Founded
2015-01-01, Year

Headquarters

Postal code
98109
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
4
Total equity funding
$18.1M
Last funding
Series A / $10M / 2022-07-28
Last equity funding
Series A / $10M
Investors
5
Lead investors
2
Founders
4
Articles
2

Founders and investors

Founders

Brady BernardCarla GrandoriChristopher KempVK Gadi

Lead investors

Bangarang GroupWashington Research Foundation

Investors

Alethea Capital ManagementBangarang GroupNational Institutes of HealthVincere CapitalWashington Research Foundation